NC awarded $3M for cancer research from Susan G. Komen
Posted September 19, 2016 10:01 a.m. EDT
Updated September 19, 2016 12:06 p.m. EDT
Raleigh, N.C. — The Susan G. Komen organization announced Monday that it will provide $2,965,000 in research grants to scientists studying breast cancer in North Carolina.
The grants awarded come from the $32.7 million Susan G. Komen gave this year to support research to reduce current breast cancer deaths by 50 percent in the U.S. over the next decade. Susan G. Komen awarded these funds to breast cancer research projects that span across 23 states and seven countries.
Officials say the projects cover the entire continuum of breast cancer research, including research into metastatic disease, novel treatments for aggressive types of breast cancer, new technologies and health equity.
The $2,965,000 awarded to N.C. will fund new research for three state institutions, bringing Komen’s total research investment in the N.C. to $40,406,515 since 1982.
"For nearly 35 years our organization has been a leader in the fight to end breast cancer, changing how people think about, talk about and treat this disease," said Komen President and CEO Judy Salerno, M.D., M.S. "Not only will these grants accelerate our understanding of key areas in breast cancer research, but they include funding for early-career investigators."
Seven researchers at the University of North Carolina at Chapel Hill and at North Carolina Central University received anywhere from $120,000 to $600,000 each to study various forms of breast cancer, detection practices, treatment options and more.
"As federal research dollars become increasingly difficult to secure, these awards give promising young researchers an opportunity to establish their careers, and help ensure breakthrough breast cancer research continues for years to come," said Salerno. "Their work is essential to achieving our vision of a world without breast cancer.”
To learn more about the organization, access local resources or get involved, visit komennctc.org.